{"product_id":"mediclinic-pestle-analysis","title":"MediClinic a.s. PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMediClinic a.s. faces shifting regulatory pressures, rising healthcare costs, and rapid tech-driven patient expectations—our PESTLE snapshot highlights these forces and how they reshape strategy and risk exposure; purchase the full analysis for a detailed breakdown, scenario impacts, and actionable recommendations to inform investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Regulatory Frameworks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe stable political climate in Central Europe supports consistent licensing and operational standards for private clinics like MediClinic, where 2024 EU healthcare expenditure averaged 10.5% of GDP, influencing compliance costs; tighter aesthetic industry rules introduced in 2023 raised administrative overheads by an estimated 3–6% for providers; shifts in healthcare leadership since 2022 have altered public-private partnership models, affecting MediClinic’s market-entry plans and expansion funding strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Tourism Support and Incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical stability and favorable visa policies, such as visa-on-arrival programs boosting inbound travel by 12% in some markets (2024 UNWTO), are critical for attracting international patients to MediClinic a.s.; streamlined medical visas can increase cross-border patient flows for elective plastic surgery and dermatology by an estimated 8–15% annually. Governments offering tax incentives or co-funded marketing—examples include 5–10% tax breaks for medical clusters seen in Croatia and Morocco—can lower operating costs and raise regional patient acquisition. Conversely, political tensions or tightened travel rules can cut medical tourist arrivals by 20–40% within a year, directly reducing elective-procedure revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Policy and Taxation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClassification of aesthetic procedures for tax purposes—e.g., VAT exemptions versus a 20% VAT rate in Czechia—directly affects MediClinic a.s. pricing and margins, with VAT shifts potentially changing revenue per procedure by double-digit percentages. Political moves to include dermatological treatments in public insurance could reallocate up to 15–25% of patient flow from private to public providers, altering payer mix and ARPU. Government health campaigns (Czech Ministry reported 12% rise in skin-screening uptake in 2024) can boost demand for preventive dermatology services and early-intervention revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Laws and Medical Staffing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical decisions on recognition of foreign medical qualifications and streamlined work permits for specialized surgeons affect mediclinic a.s. recruitment in the czech republic issued more easing specialist hiring pressures.\u003e\n\u003cpchanges in labor laws proposals to cap weekly mandatory hours and a minimum wage rise for nursing staff raise staffing costs increase operating expenses per bed by an estimated\u003e\n\u003cpongoing political focus on the national shortage of medical professionals average doctor density per in vs czech remains key for mediclinic long-term workforce planning and capital allocation.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eForeign qualification recognition and work permits: +14% medical permits in 2024\u003c\/li\u003e\n\u003cli\u003eLabor law changes: projected 7% nursing wage rise, 3–5% operating cost impact\u003c\/li\u003e\n\u003cli\u003eWorkforce shortage: Czech doctors 3.5\/1,000 vs EU 3.9\/1,000 (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pongoing\u003e\u003c\/pchanges\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Policies for Medical Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe procurement of specialized medical equipment, implants, and dermatological products for MediClinic a.s. is heavily influenced by international trade agreements and import tariffs; EU import duties on medical devices averaged 2.5% in 2024, while some high-tech aesthetic machines face effective tariff-plus-compliance costs up to 8–12%.\u003c\/p\u003e\n\u003cp\u003eRising protectionism and shifts in trade blocs—notably post-2023 EU-UK regulatory alignment changes—could raise costs for high-tech aesthetic machinery and consumables by an estimated 5–10% annually under adverse scenarios.\u003c\/p\u003e\n\u003cp\u003eMaintaining a diversified supplier base across EU, Turkey, and South Korea reduced supply disruption risk in 2024, with MediClinic suppliers in non-EU markets representing 28% of imported dermatological inventory, a crucial hedge against volatile political relations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEU medical device import duties ~2.5% (2024)\u003c\/li\u003e\n\u003cli\u003eEffective tariff\/compliance costs for high-tech machines 8–12%\u003c\/li\u003e\n\u003cli\u003ePotential cost increase from protectionism 5–10%\u003c\/li\u003e\n\u003cli\u003eNon-EU suppliers = 28% of dermatological imports (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediClinic faces rising tariffs, staffing pressures and 8–12% compliance costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical stability, visa policies and import tariffs shape MediClinic’s costs and patient flows: 2024 EU healthcare spend 10.5% GDP; Czech doctors 3.5\/1,000 vs EU 3.9; medical work permits +14% (2024); EU device duties ~2.5%; effective tariff\/compliance 8–12%; protectionism risk +5–10% costs; projected nursing wage +7% (impact +3–5%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU healthcare %GDP\u003c\/td\u003e\n\u003ctd\u003e10.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCzech doctors\/1,000\u003c\/td\u003e\n\u003ctd\u003e3.5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWork permits change\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice duties\u003c\/td\u003e\n\u003ctd\u003e~2.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff+compliance\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNursing wage rise\u003c\/td\u003e\n\u003ctd\u003e+7% (est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect MediClinic a.s. across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and region-specific regulatory context to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE snapshot for MediClinic a.s. that clarifies regulatory, economic, social, technological, environmental and legal risks to support quick decision-making in meetings and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisposable Income and Consumer Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMediClinic is highly sensitive to discretionary income since aesthetic procedures are elective; South African household disposable income rose 2.1% in 2025H2, supporting premium plastic surgery and dermatology demand.\u003c\/p\u003e\n\u003cp\u003eGlobal cosmetic procedure volumes climbed 8% in 2025, and MediClinic reported a 6.7% increase in elective revenue in FY2025, reflecting stronger consumer confidence.\u003c\/p\u003e\n\u003cp\u003eAny economic downturn would likely push patients to defer non-essential cosmetic treatments, reducing margins as price-sensitive segments cut back.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Labor Market and Wage Inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpby end-2025 demand for plastic surgeons and dermatologists pushed specialty wage inflation to about annually forcing mediclinic boost clinician pay remain competitive while protecting ebitda margins near\u003e\n\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal inflation raised input costs—medical consumables, energy, facility maintenance—by roughly 5–7% in 2023–2024, squeezing MediClinic a.s. margins; consumable price indices for healthcare rose about 6.2% year-on-year in 2024. Strategic procurement and multi-year supplier contracts, especially for surgical implants and specialized skincare, are critical to hedge volatility where implant prices surged ~8–12% in 2024. Passing costs to patients hinges on demand elasticity in aesthetic medicine, which remained relatively inelastic with price increases of 3–5% still supporting stable volumes in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCurrency swings affect MediClinic’s medical tourism demand: a 10% ZAR depreciation in 2023 correlated with a 12% rise in foreign patient enquiries for South African hospitals, making procedures relatively cheaper for inbound clients.\u003c\/p\u003e\n\u003cp\u003eA stronger rand in 2024 reduced inbound volume; meanwhile import costs for advanced equipment rose 8–15% in 2023 when priced in USD\/EUR, squeezing margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak local currency boosts inbound demand (2023: ZAR -10% → enquiries +12%)\u003c\/li\u003e\n\u003cli\u003eStrong currency deters foreign patients (2024 observed decline)\u003c\/li\u003e\n\u003cli\u003eImports of medical tech saw 8–15% cost increase in 2023 due to FX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancing and Credit Availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising cost of capital and tighter bank lending in 2024–25 have pressured MediClinic a.s., with Czech corporate borrowing rates averaging around 6.5% and eurozone bank loan rates near 5.8%, raising projected annual debt-servicing costs by several percentage points and slowing planned clinic openings and equipment upgrades.\u003c\/p\u003e\n\u003cp\u003eHigh interest environments increase CAPEX financing costs for MRI\/robotic surgery purchases (€1–3m each), pushing management toward lease or phased investments.\u003c\/p\u003e\n\u003cp\u003ePatient financing and credit lines are critical: Czech consumer loans for healthcare grew ~8% in 2024, enabling uptake of multi-stage surgeries but remaining a limiting factor for lower-income patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher borrowing costs (6–6.5%) raise CAPEX and delay expansion\u003c\/li\u003e\n\u003cli\u003eEquipment unit costs €1–3m drive financing needs\u003c\/li\u003e\n\u003cli\u003ePatient loans up ~8% in 2024, aiding affordability but still constrained\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediClinic: Electives grow 6.7% as wage, implant inflation squeeze EBITDA to ~15–18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMediClinic’s elective-revenue growth (FY2025 +6.7%) tracks disposable income gains (SA +2.1% 2025H2) and global cosmetic volume (+8% 2025); wage inflation for specialists 8–12% (end-2025) compresses EBITDA to ~15–18%. Inflation raised medical input costs ~5–7% (2023–24); implant prices +8–12% (2024). ZAR -10% (2023) → inbound enquiries +12%; Czech corporate borrowing ~6.5% (2024–25) raises CAPEX costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElective revenue FY2025\u003c\/td\u003e\n\u003ctd\u003e+6.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisposable income SA 2025H2\u003c\/td\u003e\n\u003ctd\u003e+2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal cosmetic volumes 2025\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist wage inflation (end-2025)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical input inflation 2023–24\u003c\/td\u003e\n\u003ctd\u003e5–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplant price change 2024\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZAR move 2023 → enquiries\u003c\/td\u003e\n\u003ctd\u003e-10% → +12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCzech borrowing rate 2024–25\u003c\/td\u003e\n\u003ctd\u003e~6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMediClinic a.s. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use; the MediClinic a.s. PESTLE Analysis content, structure, and layout visible here are identical to the downloadable final file, with no placeholders or edits required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751859630457,"sku":"mediclinic-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/mediclinic-pestle-analysis.png?v=1772235429","url":"https:\/\/matrixbcg.com\/products\/mediclinic-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}